product summary
Loading...
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
MDM2 Monoclonal Antibody (IF2)
catalog :
33-7100
quantity :
50 ug
price :
US 409.00
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
IF2
reactivity :
human
application :
western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, immunohistochemistry - paraffin section, immunohistochemistry - frozen section
more info or order :
Invitrogen product webpage
citations: 42
Published Application/Species/Sample/DilutionReference
  • western blot; human; loading ...; fig 5a
Ren Z, Aerts J, Vandenplas H, Wang J, Gorbenko O, Chen J, et al. Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2. Cell Death Dis. 2016;7:e2560 pubmed publisher
  • western blot; human; 1:500; loading ...; fig 2b
Wei T, Biskup E, Gjerdrum L, Niazi O, Ødum N, Gniadecki R. Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma. Oncotarget. 2016;7:48391-48400 pubmed publisher
  • immunohistochemistry; human
Saâda Bouzid E, Burel Vandenbos F, Ranchère Vince D, Birtwisle Peyrottes I, Chetaille B, Bouvier C, et al. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas. Mod Pathol. 2015;28:1404-14 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:50
Weingertner N, Neuville A, Chibon F, Ray Coquard I, Marcellin L, Ghnassia J. Myxoid liposarcoma with heterologous components: dedifferentiation or metaplasia? A FISH-documented and CGH-documented case report. Appl Immunohistochem Mol Morphol. 2015;23:230-5 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:50
Righi A, Gambarotti M, Benini S, Gamberi G, Cocchi S, Picci P, et al. MDM2 and CDK4 expression in periosteal osteosarcoma. Hum Pathol. 2015;46:549-53 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100
Ortega P, Suster D, Falconieri G, Zambrano E, Moran C, Morrison C, et al. Liposarcomas of the posterior mediastinum: clinicopathologic study of 18 cases. Mod Pathol. 2015;28:721-31 pubmed publisher
  • western blot; human; fig 5
Qiu H, Zhang L, Ren C, Zeng Z, Wu W, Luo H, et al. Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/β-catenin signaling. PLoS ONE. 2013;8:e56959 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100
Yakkioui Y, Temel Y, Creytens D, Jahanshahi A, Fleischeuer R, Santegoeds R, et al. A comparison of cell-cycle markers in skull base and sacral chordomas. World Neurosurg. 2014;82:e311-8 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100; tbl 1.
Yoshida A, Ushiku T, Motoi T, Beppu Y, Fukayama M, Tsuda H, et al. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype. Am J Surg Pathol. 2012;36:423-31 pubmed publisher
  • immunohistochemistry; human; 1:25; fig 6
Dujardin F, Binh M, Bouvier C, Gomez Brouchet A, Larousserie F, Muret A, et al. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol. 2011;24:624-37 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100; fig 2
Yoshida A, Ushiku T, Motoi T, Shibata T, Fukayama M, Tsuda H. Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant. Am J Surg Pathol. 2010;34:1361-6 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100; fig 4
Yoshida A, Ushiku T, Motoi T, Shibata T, Beppu Y, Fukayama M, et al. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol. 2010;23:1279-88 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100
Horvai A, Devries S, Roy R, O Donnell R, Waldman F. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod Pathol. 2009;22:1477-88 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:50; fig 1
Daugaard S, Christensen L, Høgdall E. Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40. APMIS. 2009;117:518-25 pubmed publisher
  • immunohistochemistry; human; fig 2
Nahal A, Meterissian S. Lipoleiomyosarcoma of the rectosigmoid colon: a unique site for a rare variant of liposarcoma. Am J Clin Oncol. 2009;32:353-5 pubmed publisher
  • immunohistochemistry; human; fig 2
Amiot A, Dokmak S, Sauvanet A, Vilgrain V, Bringuier P, Scoazec J, et al. Sporadic desmoid tumor. An exceptional cause of cystic pancreatic lesion. JOP. 2008;9:339-45 pubmed
  • immunohistochemistry - paraffin section; human; 1:100
Horvai A, Schaefer J, Nakakura E, O Donnell R. Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. Mod Pathol. 2008;21:517-24 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100; tbl 1
Bosco M, Allia E, Coindre J, Odasso C, Pagani A, Pacchioni D. alpha-fetoprotein expression in a dedifferentiated liposarcoma. Virchows Arch. 2006;448:517-20 pubmed
  • immunohistochemistry - paraffin section; human; 1:200; tbl 1
Mentzel T, Toennissen J, Rutten A, Schaller J. Palmar atypical lipomatous tumour with spindle cell features (well-differentiated spindle cell liposarcoma): a rare neoplasm arising in an unusual anatomical location. Virchows Arch. 2005;446:300-4 pubmed
  • immunohistochemistry - frozen section; human; 1:100; fig 3
Coindre J, Hostein I, Maire G, Derré J, Guillou L, Leroux A, et al. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol. 2004;203:822-30 pubmed
  • immunohistochemistry - paraffin section; human
Coindre J, Mariani O, Chibon F, Mairal A, De Saint Aubain Somerhausen N, Favre Guillevin E, et al. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol. 2003;16:256-62 pubmed
Maietta I, Del Peschio F, Buonocore P, Viscusi E, Laudati S, Iannaci G, et al. p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors. Cancers (Basel). 2022;15: pubmed publisher
Zhan Y, Zhou X, Peuget S, Singh M, Peyser B, Fan Z, et al. Decreased DNA Damage and Improved p53 Specificity of RITA Analogs. Mol Cancer Ther. 2022;21:1524-1534 pubmed publisher
Timmerman D, Eleveld T, Gillis A, Friedrichs C, Hillenius S, Remmers T, et al. The Role of TP53 in Cisplatin Resistance in Mediastinal and Testicular Germ Cell Tumors. Int J Mol Sci. 2021;22: pubmed publisher
Ma S, Yan J, Barr T, Zhang J, Chen Z, Wang L, et al. The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity. J Exp Med. 2021;218: pubmed publisher
Trautmann M, Rehk xe4 mper J, Gevensleben H, Becker J, Wardelmann E, Hartmann W, et al. Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis - A systematic analysis of 204 cases. Sci Rep. 2020;10:3368 pubmed publisher
Sladky V, Knapp K, Soratroi C, Heppke J, Eichin F, Rocamora Reverte L, et al. E2F-Family Members Engage the PIDDosome to Limit Hepatocyte Ploidy in Liver Development and Regeneration. Dev Cell. 2020;52:335-349.e7 pubmed publisher
Pellegrino M, Rizza P, Donà A, Nigro A, Ricci E, Fiorillo M, et al. FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer. Cancers (Basel). 2019;11: pubmed publisher
Kim Y, Kim M, Park H, Yu D, Jung K, Song K, et al. Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology. Lab Invest. 2019;: pubmed publisher
Cornillie J, Wozniak A, Li H, Wang Y, Boeckx B, Gebreyohannes Y, et al. Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing. Mol Cancer Ther. 2019;18:1168-1178 pubmed publisher
Berthier S, Larrouquere L, Champelovier P, Col E, Lefebvre C, Cottet Rouselle C, et al. A New Patient-Derived Metastatic Glioblastoma Cell Line: Characterisation and Response to Sodium Selenite Anticancer Agent. Cancers (Basel). 2018;11: pubmed publisher
Wylleman R, Debiec Rychter M, Sciot R. A rare case of atypical/anaplastic meningioma with MDM2 amplification. Rare Tumors. 2018;10:2036361318779511 pubmed publisher
Yang S, Lee J, Guo J, Kuo S, Tien Y, Kuo T, et al. Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. PLoS ONE. 2017;12:e0180628 pubmed publisher
Wang X, Zhang S, Bao J, Liu F. Oridonin synergizes with Nutlin-3 in osteosarcoma cells by modulating the levels of multiple Bcl-2 family proteins. Tumour Biol. 2017;39:1010428317701638 pubmed publisher
Gottlieb A, Althoff K, Grunewald L, Thor T, Odersky A, Schulte M, et al. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status. Oncotarget. 2017;8:27882-27891 pubmed publisher
Grünewald I, Trautmann M, Busch A, Bauer L, Huss S, Schweinshaupt P, et al. MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas. Oncotarget. 2016;7:75261-75272 pubmed publisher
Helbig D, Ihle M, Pütz K, Tantcheva Poor I, Mauch C, Büttner R, et al. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget. 2016;7:21763-74 pubmed publisher
Künkele A, De Preter K, Heukamp L, Thor T, Pajtler K, Hartmann W, et al. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Neuro Oncol. 2012;14:859-69 pubmed publisher
Weaver J, Goldblum J, Turner S, Tubbs R, Wang W, Lazar A, et al. Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. Mod Pathol. 2009;22:66-70 pubmed publisher
Binh M, Garau X, Guillou L, Aurias A, Coindre J. Reproducibility of MDM2 and CDK4 staining in soft tissue tumors. Am J Clin Pathol. 2006;125:693-7 pubmed
Khor L, DeSilvio M, Al Saleem T, Hammond M, Grignon D, Sause W, et al. MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer. 2005;104:962-7 pubmed
Wang Y, Lin R, Tan Y, Chen J, Chen C, Wang Y. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. J Clin Oncol. 2005;23:154-64 pubmed
product information
Product Type :
Antibody
Product Name :
MDM2 Monoclonal Antibody (IF2)
Catalog # :
33-7100
Quantity :
50 ug
Price :
US 409.00
Clonality :
Monoclonal
Purity :
protein A
Host :
Mouse
Reactivity :
Human
Applications :
Immunocytochemistry: 1:25-1:200, Immunohistochemistry (Paraffin): 1:25-1:200, Immunoprecipitation: 1-5 ug/mL, Western Blot: 0.5-2 ug/mL
Species :
Human
Clone :
IF2
Isotype :
IgG2b, kappa
Storage :
-20 C, Avoid Freeze/Thaw Cycles
Description :
MDM2 is a ubiquitin ligase for p53 and plays a central role in regulation of the stability of p53. MDM2 is located on chromosome 12 on the q arm. Akt-mediated phosphorylation of MDM2 at Ser166 and Ser186 increases its interaction with p300, allowing MDM2-mediated ubiquitination and degradation of p53. Phosphorylation of MDM2 also blocks its binding to p19ARF, increasing the degradation of p53. MDM2 has also been shown to negatively regulate p53 function. MDM2 binds and inhibits transactivation role played by p53 and overexpression of MDM2 can result in the inactivation of p53 and decrease its tumor suppressor function. Another process by which MDM2 can inactivate p53 is by degrading p53 as the protein also possesses E3 ubiquitin ligase activity. Further, MDM2 plays important roles in apoptosis and cell cycle. MDM2 is over expressed in a wide range of human malignancies including soft tissue carcinomas and breast cancer. In addition to p53, MDM2 is involved in processes of cell cycle, apoptosis, and tumorigenesis through interactions with proteins that include retinoblastoma 1 and ribosomal protein L5. More than 40 different alternatively spliced transcript variants of MDM2 have been isolated from both tumor and normal tissues.
Immunogen :
Synthetic peptide derived from the n-terminal region of human MDM2
Format :
Liquid
Applications w/Dilutions :
Immunocytochemistry: 1:25-1:200, Immunohistochemistry (Paraffin): 1:25-1:200, Immunoprecipitation: 1-5 ug/mL, Western Blot: 0.5-2 ug/mL
Aliases :
1700007J15Rik; AA415488; ACTFS; double minute 2; double minute 2 protein; double minute 2, human homolog of; p53-binding protein; E3 ubiquitin-protein ligase Mdm2; Hdm2; HDMX; HGNC:6973; human homolog of; MDM2; Mdm-2; MDM2 oncogene, E3 ubiquitin protein ligase; Mdm2 p53 binding protein homolog; MDM2 proto-oncogene; MDM2 proto-oncogene, E3 ubiquitin protein ligase; MDM2 variant FB28; Mdm2, p53 E3 ubiquitin protein ligase homolog; Mdm2, transformed 3T3 cell double minute 2, p53 binding protein; MGC5370; MGC71221; oncoprotein Mdm2; OTTHUMP00000183490; OTTHUMP00000183492; OTTHUMP00000183494; OTTHUMP00000183495; OTTHUMP00000183496; OTTHUMP00000183497; p53 E3 ubiquitin protein ligase; p53-binding protein Mdm2; RING-type E3 ubiquitin transferase Mdm2; transformed mouse 3T3 cell double minute 2
more info or order :
Invitrogen product webpage
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA